Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Friday, April 8, 2011

Table of FMO3 variants provided by Dr John Cashman

Table of FMO3 variants provided by Dr John Cashman 

Dr John Cashman kindly provided some of his research papers for us to view at the Washington meetup. We have chosen to look at the table of FMO3 variants in one of these papers.

As seen in Prof Elizabeth Shephard's slideshow, the FMO3 protein consists of 532 amino acids. Whilst building these amino acids, in theory it means there could be 532 points where mutations could occur that would affect the construction of the final FMO3 protein.

In this table, Dr Cashman has listed some of the common amino acid numbers where mutations occur. Some are severe mutations, other have less or no effect, although some can reduce activity if in combination with another (such as 158 - 258)

Notice that one change to amino acid 158 is about 40% common in ethnic groups.

2.5% have a combo of 158 - 308 which is said to be present in 2.5% of the population. However, this is only regarded as likely to cause a mild deficiency in FMO3 function if both the mutations are on the same chromosome (i.e. from the same parent) .

The paper also lists some drugs that commonly use FMO3 function and the affect a deficiency may have on them.

0 comments:

Post a Comment